In the article titled " e Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-erapy Induced Osteoporosis in Patients with Prostate Cancer" [ ], there was an error regarding the FRAX5 tool, which should be clari ed as follows. e article notes: "As a result of the potential consequences of ADT, expert guideline recommendations advocate for assessing men prescribed ADT for osteoporosis and to estimate the baseline fracture risk using an assessment tool, such as the World Health Organization fracture risk assessment tool [6, 21, 32, 33] ". However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX5 tool or its recommendations [ ]. e metabolic bone disease unit at the University of She eld that developed FRAX5 was a WHO Collaborating Centre from to , but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.
